Lundbeck Signs Near €1Bn Acquisition of Swiss Parkinson’s Biotech

Danish pharma Lundbeck has decided to boost its pipeline with the acquisition of Prexton Therapeutics. The deal grants Lundbeck with global rights to foliglurax, a drug to reduce the “off” time periods when Parkinson’s motor complications come back as levodopa medication stops working optimally.Lundbeck will pay Prexton €100M upfront and up to €805M as the drug meets several development, regulatory and sales milestones. Foliglurax entered a Phase II trial in Parkinson’s last July and data is expected in mid-2018, meaning the first of these milestones could be achieved this same year.